Aptevo Therapeutics Inc.
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -70.66% | 121.98% | 139.44% | 204.41% | -93.73% |
| Gross Profit | 70.66% | -121.98% | -139.44% | -204.41% | 93.73% |
| SG&A Expenses | 15.14% | 12.34% | -6.52% | -13.79% | -13.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.92% | 8.51% | -6.36% | -14.26% | -14.81% |
| Operating Income | -29.92% | -8.51% | 6.36% | 14.26% | 14.81% |
| Income Before Tax | -7.61% | -10.24% | 4.84% | 13.21% | -29.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.61% | -10.24% | 4.84% | 13.21% | -29.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.61% | -11.60% | 3.72% | 12.27% | -38.58% |
| EBIT | -29.92% | -8.51% | 6.36% | 14.26% | 14.81% |
| EBITDA | -30.48% | -9.34% | 5.80% | 13.83% | 14.35% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |